Skip to content
lifestyle.faithfamilyamerica.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ELI LILLY AND COMPANY
Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
September 1, 2026
New Phase 3b data on Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
August 31, 2026
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
August 31, 2026
FDA approves Lilly’s Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
August 28, 2026
FDA approves Lilly’s Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
August 28, 2026
Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
August 26, 2026
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
August 12, 2026
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
August 5, 2026
Lilly’s olomorasib receives U.S. FDA’s Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
August 3, 2026
Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
July 23, 2026
1
2
3
…
5
Next Page
→